MedTrace Logo

Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea

NCT06331533 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-29

No results posted yet for this study

Summary

Investigation of the effectiveness of intradermal botulinum toxin A treatment in the treatment of erythematotelangiectatic rosacea (ETR) using clinical, biophysical, dermatoscopic and videocapillaroscopy.

Conditions

  • Erythematotelangiectatic Rosacea

Interventions

DRUG

Botulinum toxin A

Intradermal botulinum toxin A was applied to the treatment side

DRUG

Placebo

NaCl was injected into the placebo side

Sponsors & Collaborators

  • Istanbul Training and Research Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-05-01
Completion
2023-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06331533 on ClinicalTrials.gov